Skip to main content

Table 5 Microbiologic response by patient at test-of-cure visit (ME population)

From: Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial

 

Tigecycline

Imipenem/cilastatin

Difference (Tigecycline-Imipenem/cilastatin)

 

N

% (95% CI)

N

% (95% CI)

% (95% CI)

Overall

     

   Eradication

45/52

86.5

(74.2, 94.4)

47/48

97.9

(88.9, 99.9)

-11.4

(-23.5, 0.7)

   Persistence

7/52

13.5

(5.6, 25.8)

1/48

2.1

(0.1, 11.1)

 

   Superinfection

0/52

0

(0.0, 6.8)

0/48

0

(0.0, 7.4)

 

Monomicrobial

     

   Eradication

30/33

90.9

(75.7, 98.1)

25/26

96.2

(80.4, 99.9)

-5.2

(-22.0, 13.7)

   Persistence

3/33

9.1

(1.9, 24.3)

1/26

3.8

(0.1, 19.6)

 

   Superinfection

0/33

0

(0.0, 10.6)

0/26

0

(0.0, 13.2)

 

Polymicrobial

     

   Eradication

15/19

78.9

(54.4, 93.9)

22/22

100.0

(84.6, 100.0)

-21.1

(-46.1, 2.2)

   Persistence

4/19

21.1

(6.1, 45.6)

0/22

0

(0.0, 15.4)

 

   Superinfection

0/19

0

(0.0, 17.6)

0/22

0

(0.0, 15.4)